Posts for Ticker ‘LXRX’

Top Day Trader Alerts (BBY, BCRX, C, DNDN, ING, LXRX, YHOO)

These are this morning’s top pre-market day trader alert stocks.  We have more color and more detail on price and volume analysis linked through to each at VSInvestor.com:

Best Buy Co. (NYSE: BBY) is holding up better than many might guess considering how much it has run up. This is after light earnings.

BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) is fairly close to 52-week highs after signing three partnerships for Peramivir for influenza outside the U.S.

Citigroup Inc. (NYSE: C) is down but only marginally on reports of a ‘possible’ stake sale by The U.S. Government.

Dendreon Corp. (NASDAQ: (DNDN) is giving back a portion of yesterday’s gains on merger rumors.

ING Group (NYSE: ING) will be an active ADR today after the EU may block a settlement.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is surging as a top bio-winner after moving to Phase 2 clinical trial of LX4211 in patients with type 2 diabetes.

Yahoo! Inc. (NASDAQ: YHOO) is soaring to highs not seen since July on yet another upgrade.

You can join our open email distribution list which goes out several times per week for top day trader alerts, top analyst upgrades and downgrades, IPO’s, key secondary offerings, guru investor data on Buffett and others, mergers, and more.

JON C. OGG
September 15, 2009

Posted on: September 15, 2009 – 8:57 am in After-Hours Activity, Pre-Market Activity, Trading Alert, , , , , , ,

Lexicon New Alzheimer’s Disease Trial Dosing (LXRX)

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has announced that dosing has commenced in its Phase IIa clinical trial with LX6171.  This is an oral drug candidate that is implied for the treatment of cognitive impairment disorders such as Alzheimer’s disease, schizophrenia, and vascular dementia.

The initial stage of the trial will assess the bioavailability of a new oral-suspension formulation in healthy elderly subjects with a second stage evaluating safety, tolerability and cognitive effects in elderly subjects with age-associated memory impairment.

This was issued ahead of its R&D webcast at Noon EST today.  Shares have not traded in pre-market trading and closed at $3.20 yesterday; its 52-week trading range is $2.80 to $4.40.

Jon C. Ogg
December 5, 2007

Jon Ogg can be reached at jonogg@247wallst.com; he does not own securities in the companies he covers.

Posted on: December 5, 2007 – 8:42 am in Biotech, ,

Pre-Market Stock News (June 18, 2007)

(AA) An ALCOA bid from BHP may be kindled according to numerous M&A reports.
(ADVNA) Advanta trades ex-split to reflect a 3-2 stock split.
(AGU) Agrium said earnings will be at or above the upper end of its $1.45 to $1.55 range.
(BBI) Blockbuster is going to favor the Blu-Ray HD discs.
(BNHNA) Benihana $0.35 EPS vs $0.30e.
(BWLD) Buffalo Wild Wings trades ex-split to reflect a 2-1 stock split.
(CEPH) Cephalon received FDA Marketing approval of Nuvigil for excessive sleepiness.
(CVTX) CV Therapeutics traded up on Cramer recommendation.
(DJ) Dow Jones may get a rival bid from Pearson and General Electric.
(ECIL) ECI Telecom in discussions for potential takeovers at $10.00 per share.
(ENCY) Encysive Pharma trading down 50%; announced third ‘approvable’letter from FDA for Thelin for treating pulmonary arterial hypertension, but it did not demonstrate the evidence of effectiveness needed for approval and may have to drastically cut costs.
(ESC) Emeritus Corp announces a 10.5 million share common stock offering; 9 million shares were from the company and 1.5 million from selling shareholders.
(FRN) Friendly Ice Cream going private at $15.50.
(FTEK) Fuel-Tech gets two orders totaling $2 million.
(GCO) Genesco gets $54.50 per share offer and buyout from Finish Line.
(KERX) Keryx Bio announced its CFO is resigning.
(LXRX) Lexicon Pharma secured a major investment in the company as a two part investment: $205 million and $60 million.
(MSFT) Microsoft making investment in Chinese television and media makers to change IPTV to Mediaroom.
(NVDA) NVIDIA noted as speculative chip play by Cramer.
(OBAS) Optibase won encoder pact from Huawei for IPTV.
(PAY) Verifone announced a $275 million senior convertible note offering.
(THRM) Thermage says FDA clears indication for Thermacool system.
(VICL) Vical licensee AnGes MG announces positive results of Phase 3 angiogenesis trial in Japan.
(VRAZ) Veraz platform chosen by Golden Telecom for an upgrade of its TDM network to a next-generation network.
(XFML) Xinhua Finance Media wins contract to re-brand Hebei Movie & Drama TV channel.

Jon C. Ogg
June 18, 2007

Posted on: June 18, 2007 – 6:53 am in Pre-Market Activity, , , , , , , , , , , , , , , , , , , , , , , , ,

Lexicon Pharmaceuticals: Back From The Depths With New Investors (LXRX)

Lexicon Pharmaceuticals, Inc. (LXRX-NASDAQ) is a biotech company that many have not heard of, and those who do know it may have a painful history from it.  Anyone who got in the stock over the last week will have a new cheer on Monday as the company has secured a $205 million investment from The Invus Group, LLC over the course of 2007 with the potential for up to an additional $345 million over the next four years.

Simultaneously, Lexicon announced it has entered into a $60 million product development collaboration with Symphony Capital Partners, L.P. and its co-investors ("Symphony") to move its first three drug candidates into advanced clinical development:

-LX6171 for cognitive disorders, currently completing Phase 1b;
-LX1031 for irritable bowel syndrome, currently in Phase 1b;
-LX1032 for gastrointestinal disorders, currently in preclinical development.

Back in 2000, this stock traded north of $40.00, then traded to under $10.00 in 2001, and the stock slid lower and lower to around $3.00 recently.  This is the sort of investment news that brings biotech zombies back to life.  Lexicon had a market cap of $241 million as of Friday’s close, and it had just over $59.5 million in cash and equivalents and more than $98 million in total liabilities as of its most recent quarter.  Below are the details of each transaction from the press release:

Read More »

Posted on: June 18, 2007 – 3:31 am in Biotech,